专肽生物_定制多肽合成服务_多肽合成定制服务_多肽合成厂家_多肽合成公司

Portion of EBV BZLF-1

CEF15 是 EB 病毒 BZLF‑1 来源肽，用于研究 EB 病毒裂解周期蛋白保守基序。其紧凑结构支持 β 转角行为与溶剂暴露残基定位。研究者通过构象变异定义表位特征。该分子丰富 EB 病毒肽结构研究。

CEF15 is a BZLF-1-derived peptide used to investigate conserved motifs in EBV lytic-cycle proteins. Its compact structure supports mapping of β-turn behavior and solvent-exposed residues. Researchers analyze conformational variability to define epitope signatures. The molecule enriches EBV peptide-structure studies.

EBV BZLF1(190-197)是一种免疫显性CEF控制肽，源自Epstein-Barr病毒(EBV)。EBV BZLF1(190-197)是CD8+T细胞的合适表位，可用于刺激IFNg的释放。EBV BZLF1(190-197)的CD8阳性的细胞毒性T淋巴细胞(CTL)反应具有多样性，并且能够交叉识别来自宿主自身蛋白和细菌蛋白的类似肽段。EBV BZLF1(190-197)可用于自身免疫疾病的研究。
 

Definition

The CEF control peptides are 8-12 amino acids in length, with sequences derived from the human Cytomegalovirus, Epstein-Barr Virus and Influenza Virus1 These peptides are used in the stimulation of IFNg release from CD8+ T cells in individuals with defined HLA types1.  They are useful as positive control peptides in several cytokine assays such as Elispot.

Discovery

CEF peptides were first selected in 2002 based on their ability to recognize CD8+ T cells1.

Classification

They are derived from epitopes of viruses and hence have antigenic properties1.

Structural Characteristics

CEF peptides are 8-11 amino acids long with sequences: GILGFVFTL (Influenza A, HLA-A2), FMYSDFHFI (Influenza A, HLA-A2), CLGGLLTMV (EBV, HLA-A2), GLCTLVAML (EBV, HLA-A2), NLVPMVATV (HCMV, HLA-A2).

Mode of action

CEF peptides are effective epitopes for CD8+ T cells2.  They bind to these cells and trigger the production of IFNg.

Functions

CEF control peptides are used as positive control in Elispot assay that is used to investigate specific immune responses in various diseases including infections, cancer, allergies and autoimmune diseases2.  In this case the CEF peptides ensure that the cells under study are active and viable2.  Elispot is also useful in the development of vaccines especially for HIV where CEF peptides are used also as controls2.

References

1.     Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, Ferrari G, Birx DL, Cox JH (2002). A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays, J Immunol Methods, 260, 157-172.

2.     Gazagne A, Claret E, Wijdenes J, Yssel H, Bousquet F, Levy E, Vielh P, Scotte F, Goupil T, Fridman WH, Tartour E (2003). A Fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines, J Immunol Methods, 283(1-2), 91-98.

Bogedain, C. et al. J. Virol. 69, 4872 (1995); Steven, N. et al. J. Exp. Med. 185, 1605 (1997).